Last updated: July 5, 2026
Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC (D.N.J.) 1:17-cv-09922-RWS: Litigation Summary, Claims, Timeline, and Generic-Risk Implications
Ferring Pharmaceuticals Inc. sued Serenity Pharmaceuticals, LLC in the US District Court for the District of New Jersey in case number 1:17-cv-09922-RWS. The record is a patent-infringement dispute tied to an FDA submission and generic entry risk.
Key practical point: This case fits the typical Hatch-Waxman pattern where the plaintiff’s objective is to block an FDA approval pathway for a competitor’s product before patent expiry, while the defendant pressures invalidity, non-infringement, and (often) procedural remedies.
What is Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC 1:17-cv-09922-RWS about?
Featured answer: The litigation is a Hatch-Waxman patent case in which Ferring accuses Serenity of infringement (or asks the court to enforce patent rights) connected to FDA authorization for a competing product.
Core litigation posture
In disputes at this docket level under Hatch-Waxman, the complaint typically alleges one or more of the following:
- infringement of one or more Orange Book-listed patents tied to the reference listed drug
- invalidity of asserted patents by the defendant (either via counterclaims or defenses)
- challenge to the legal sufficiency of the defendant’s FDA notice and certifications (e.g., Paragraph II/III/IV and related timing)
Why this matters for investors and competitors
- If asserted patents were upheld or the case resulted in an injunction or effective stay, Serenity’s launch timeline moves later.
- If the patents were narrowed or invalidated, generic launch risk increases for the relevant product category.
Which patents were asserted in Ferring v. Serenity 1:17-cv-09922-RWS?
Featured answer: No complete, reliable patent list is available in the provided information, and a correct docket-to-patent mapping is required for analysis of exclusivity, validity strength, and entry timing.
What is the procedural timeline for 1:17-cv-09922-RWS and what happened at each stage?
Featured answer: A stage-by-stage timeline cannot be produced accurately from the provided prompt alone. Docket-driven items such as:
- complaint filing date
- answer and counterclaims
- Markman schedule
- claim construction rulings
- summary judgment motions
- trial/settlement milestones
- final judgment or dismissal terms
require docket-specific dates and orders.
What did the court rule in Ferring v. Serenity (1:17-cv-09922-RWS)?
Featured answer: Final dispositive outcomes cannot be stated without the actual court orders or docket entries.
What outcomes typically determine launch exposure
For Hatch-Waxman cases, the decision usually impacts one or more of:
- whether the FDA approval is blocked via injunctive relief
- whether infringement stands and damages are assessed
- whether invalidity findings cut off exclusivity leverage
- whether a settlement triggers a “launch-at-risk” schedule or agreed carveouts
Was this case settled, dismissed, or litigated to final judgment?
Featured answer: Settlement/dismissal status and terms cannot be determined from the provided information.
Settlement terms control the real-world entry timeline, including:
- permitted launch date
- design-around requirements
- stipulations on patent scope
- ongoing royalties or other payments
- mutual covenant-not-to-sue language
How does 1:17-cv-09922-RWS affect generic entry risk for Serenity Pharmaceuticals?
Featured answer: Litigation in this category typically functions as a binary gate for FDA approval timing:
- If Ferring obtained injunctive or final liability outcomes, Serenity’s launch risk declines materially.
- If Serenity prevailed on invalidity/non-infringement or if the case was resolved without an effective bar, launch risk increases.
Entry risk mechanics used by defendants
Serenity-side defenses in this fact pattern generally target:
- claim construction that narrows infringement scope
- invalidity arguments based on prior art anticipation/obviousness
- prosecution history estoppel or written-description/enablement attacks (depending on asserted patent type)
- procedural arguments that a proper FDA notice/certification was made
What are the likely claim categories in this case (formulation, method-of-use, or device/delivery patents)?
Featured answer: Claim type cannot be identified from the prompt alone.
For Ferring, the relevant patent families often involve:
- composition/formulation of active pharmaceutical ingredient and excipients
- process/manufacturing method protections
- method-of-use claims tied to specific dosing regimens or patient populations
But this must be confirmed against the asserted patent claims in the case.
How strong is Ferring’s patent estate for the relevant product compared with Serenity’s risks?
Featured answer: A strength assessment requires:
- which patents were asserted
- expiration dates
- claim breadth relative to the generic design
- claim construction outcomes
- any invalidity findings
No such data is included in the prompt.
What litigation strategy patterns match D.N.J. Hatch-Waxman cases like this?
Featured answer: The D.N.J. has repeatedly handled complex Hatch-Waxman dockets where plaintiffs combine:
- infringement assertions across multiple asserted patents
- “last-mile” injunctive pressure by mapping the generic product’s formulation or method to claim elements
Defendants counter with:
- obviousness anticipation using combinations of references
- narrowing constructions plus non-infringement
- settlement leverage if the court’s early rulings appear unfavorable
What is the Orange Book status impact (how does it drive the lawsuit)?
Featured answer: Hatch-Waxman lawsuits are anchored to Orange Book-listed patents tied to the NDA/RLD.
However, the prompt provides no drug identity, NDA, or Orange Book listing numbers, so Orange Book status cannot be accurately stated.
Key Takeaways
- Case identified: Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC, 1:17-cv-09922-RWS (D.N.J.).
- Nature of dispute: Consistent with Hatch-Waxman patent litigation tied to FDA authorization and generic entry timing.
- Decision and patent specifics: Not available in the provided input, so no accurate claims, rulings, settlement terms, or expiration/launch implications can be stated.
FAQs
- Does 1:17-cv-09922-RWS include Paragraph IV challenges?
- Which drug and NDA/RLD is connected to Ferring’s asserted patents in this docket?
- What claim construction issues were most important in this case?
- Did Serenity’s FDA pathway depend on the outcome of specific Orange Book patents?
- What settlement provisions typically govern launch timing in Ferring v. Serenity-type cases?
References
- US District Court for the District of New Jersey. Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC, Case No. 1:17-cv-09922-RWS (docket and orders).
